

一級交互作用

2011.07.05

女性激素	ODIV	DIVINA TABLETS	Medroxyprogesterone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
女性激素	ODIV	DIVINA TABLETS	Medroxyprogesterone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
女性激素	ODIV	DIVINA TABLETS	Medroxyprogesterone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
女性激素複方	OHAV	HAVINA F.C TAB. "S.Y"	Norethindrone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
女性激素複方	OHAV	HAVINA F.C TAB. "S.Y"	Norethindrone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
女性激素複方	OHAV	HAVINA F.C TAB. "S.Y"	Norethindrone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
中樞神經系統藥物	OULT	ULTRACET TABLETS	Tramadol	抗憂鬱劑	OCYM	CYMBALTA 30MG	Duloxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
中樞神經系統藥物	OULT	ULTRACET TABLETS	Tramadol	其他治療藥物	OLEA	LEXAPRO TABLETS 10MG	Escitalopram	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
中樞神經系統藥物	OULT	ULTRACET TABLETS	Tramadol	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.

一級交互作用

2011.07.05

中樞神經系統藥物	OULT	ULTRACET TABLETS	Tramadol	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
中樞神經系統藥物	OULT	ULTRACET TABLETS	Tramadol	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
心臟用藥	ICOR	CORDARONE INJECTION	Amiodarone	恩莧類藥	ICRA	CRAVIT IV SOLUTION FOR INFUSION 5MG/ML	Levofloxacin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	ICOR	CORDARONE INJECTION	Amiodarone	抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹⁻³	Use certain MACROLIDE ANTIBIOTICS with caution² and avoid TELITHROMYCIN³ in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	ICOR	CORDARONE INJECTION	Amiodarone	心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	Delayed	Major	Probable	Serum DIGOXIN levels may be increased, resulting in an increase in the pharmacologic and toxic effects of DIGOXIN.	Monitor patients for signs and symptoms of DIGOXIN toxicity, and adjust the dose accordingly. Consider empiric reduction of the DIGOXIN dose during AMIODARONE therapy. Serum DIGOXIN levels may aid in dose adjustment.
心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Coadministration of TETRACYCLINE and DIGOXIN may result in increased serum levels of DIGOXIN in a small subset of patients (≈ 10%); DIGOXIN toxicity may occur. The effects may persist for months after stopping TETRACYCLINE.	Monitor patients for increased DIGOXIN levels and signs of DIGOXIN excess. A decreased DIGOXIN dose may be necessary. The use of the capsule formulation may minimize DRP production because of increased bioavailability.

一級交互作用

2011.07.05

心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	心臟用藥	IVER	VERPAMIL 2.5MG/ML INJECTION	Verapamil	Delayed	Major	Established	DIGOXIN effects may be enhanced. Increased DIGOXIN levels and toxicity could occur.	Monitor DIGOXIN plasma concentrations and observe patients for signs of toxicity. Adjust the dose as needed. It may be necessary to decrease the DIGOXIN dosage.
心臟用藥	OAC2	ACCUPRIL F.C. TABLETS 20 MG	Quinapril	保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	Delayed	Major	Probable	Combining ACE INHIBITORS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk (eg, renally impaired) patients.	Regularly monitor renal function and serum potassium levels in patients receiving these agents concurrently. Be prepared to adjust therapy as needed.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	恩萘類藥	ICRA	CRAVIT IV SOLUTION FOR INFUSION 5MG/ML	Levofloxacin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	恩萘類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹⁻³	Use certain MACROLIDE ANTIBIOTICS with caution² and avoid TELITHROMYCIN³ in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	Delayed	Major	Probable	Serum DIGOXIN levels may be increased, resulting in an increase in the pharmacologic and toxic effects of DIGOXIN.	Monitor patients for signs and symptoms of DIGOXIN toxicity, and adjust the dose accordingly. Consider empiric reduction of the DIGOXIN dose during AMIODARONE therapy. Serum DIGOXIN levels may aid in dose adjustment.

一級交互作用

2011.07.05

心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	Delayed	Major	Probable	Serum DIGOXIN levels may be increased, resulting in an increase in the pharmacologic and toxic effects of DIGOXIN.	Monitor patients for signs and symptoms of DIGOXIN toxicity, and adjust the dose accordingly. Consider empiric reduction of the DIGOXIN dose during AMIODARONE therapy. Serum DIGOXIN levels may aid in dose adjustment.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	恩萇類藥	OAVE	AVELOX FILM- COATED TAB. 400MG	Moxifloxacin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class A and class I ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	Delayed	Major	Suspected	Plasma concentrations of certain HMG-CoA REDUCTASE INHIBITORS may be elevated, increasing the risk of toxicity (eg, myositis, rhabdomyolysis).	If coadministration of these agents cannot be avoided, use the lowest possible HMG-CoA REDUCTASE INHIBITOR dose and advise patients to immediately report any unexplained muscle pain, tenderness, or weakness. Fluvastatin (Lescol),
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	降血脂藥	OLI4	LIPITOR FILM- COATED TABLETS 40MG	Atorvastatin	Delayed	Major	Suspected	Plasma concentrations of certain HMG-CoA REDUCTASE INHIBITORS may be elevated, increasing the risk of toxicity (eg, myositis, rhabdomyolysis).	If coadministration of these agents cannot be avoided, use the lowest possible HMG-CoA REDUCTASE INHIBITOR dose and advise patients to immediately report any unexplained muscle pain, tenderness, or weakness. Fluvastatin (Lescol),
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Established	Hypoprothrombinemic effect of oral ANTICOAGULANTS is augmented by concomitant AMIODARONE therapy.	Monitor INR closely during first 6 to 8 weeks of AMIODARONE therapy. In patients receiving AMIODARONE maintenance doses of 100, 200, 300, or 400 mg/day, reduce the WARFARIN dose by approximately 25%, 30%, 35%, or 40%, respectively, but a 30%
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	其他精神治療藥	OGEO	GEODON CAPSULES 40MG	Ziprasidone	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	ZIPRASIDONE is contraindicated in patients receiving certain ANTIARRHYTHMIC AGENTS.

一級交互作用

2011.07.05

心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹⁻³	Use certain MACROLIDE ANTIBIOTICS with caution² and avoid TELITHROMYCIN³ in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Suspected	Plasma concentrations of certain HMG-CoA REDUCTASE INHIBITORS may be elevated, increasing the risk of toxicity (eg, myositis, rhabdomyolysis).	If coadministration of these agents cannot be avoided, use the lowest possible HMG-CoA REDUCTASE INHIBITOR dose and advise patients to immediately report any unexplained muscle pain, tenderness, or weakness. Fluvastatin (<trade-name>Lescol</trade-name>),
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	抗生素－巨環類	OZIS	ZITHROMAX POWDER FOR ORAL SUSPENSION	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹⁻³	Use certain MACROLIDE ANTIBIOTICS with caution² and avoid TELITHROMYCIN³ in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	抗生素－巨環類	OZIT	ZITHROMAX 250MG TABLETS	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.¹⁻³	Use certain MACROLIDE ANTIBIOTICS with caution² and avoid TELITHROMYCIN³ in patients receiving class ΙA and class ΙΙΙ ANTIARRHYTHMIC AGENTS.
心臟用藥	OCA9	CARDIZEM RETARD 90MG	Diltiazem	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	Elevated plasma concentrations of MACROLIDE and RELATED ANTIBIOTICS, increasing the risk of cardiotoxicity.	Until more data are available, if possible, avoid coadministration of MACROLIDE and RELATED ANTIBIOTICS and DILTIAZEM.
心臟用藥	OCAR	CARDIOLOL TABLETS 10MG (PROPRANOLOL)(鋁箔/膠箔)	Propranolol	降血壓藥	OCAT	CATAPRES TABLETS 75UG (CLONIDINE HYDROCHLORIDE)	Clonidine	Delayed	Major	Suspected	Potentially life-threatening increases in BP.	Closely monitor BP after initiation or discontinuation of CLONIDINE or a BETA-BLOCKER when they are given concurrently. Discontinue either agent gradually; preferably, discontinue the BETA-BLOCKER first.

一級交互作用

2011.07.05

心臟用藥	OHEB	HERBESSER TABLETS	Diltiazem	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	Elevated plasma concentrations of MACROLIDE and RELATED ANTIBIOTICS, increasing the risk of cardiotoxicity.	Until more data are available, if possible, avoid coadministration of MACROLIDE and RELATED ANTIBIOTICS and DILTIAZEM.
心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL) "Y.S."(鋁箔/膠箔)	Verapamil	心臟用藥	OCAR	CARDIOLOL TABLETS 10MG (PROPRANOLOL)(鋁箔/膠箔)	Propranolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL)	Verapamil	心臟用藥	OKEL	KERLONE 20MG, SCORED FILM-COATED TABLET	Betaxolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL) "Y.S."(鋁箔/膠箔)	Verapamil	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Probable	Increased risk of cardiotoxicity.	Closely monitor cardiac function in patients receiving VERAPAMIL and certain MACROLIDE and RELATED ANTIBIOTICS.
心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL)	Verapamil	心臟用藥	OTE1	TENORMIN TABLETS 100MG	Atenolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL)	Verapamil	降血壓藥	OPIN	PINDOLOL TABLETS "TOWA"	Pindolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT"	Minocycline	Delayed	Major	Suspected	Coadministration of TETRACYCLINE and DIGOXIN may result in increased serum levels of DIGOXIN in a small subset of patients (& 10%); DIGOXIN toxicity may occur. The effects may persist for months after stopping TETRACYCLINE.	Monitor patients for increased DIGOXIN levels and signs of DIGOXIN excess. A decreased DIGOXIN dose may be necessary. The use of the capsule formulation may minimize DRP production because of increased bioavailability.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	Delayed	Major	Suspected	Coadministration of TETRACYCLINE and DIGOXIN may result in increased serum levels of DIGOXIN in a small subset of patients (& 10%); DIGOXIN toxicity may occur. The effects may persist for months after stopping TETRACYCLINE.	Monitor patients for increased DIGOXIN levels and signs of DIGOXIN excess. A decreased DIGOXIN dose may be necessary. The use of the capsule formulation may minimize DRP production because of increased bioavailability.

一級交互作用

2011.07.05

心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	心臟用藥	IVER	VERPAMIL 2.5MG/ML INJECTION	Verapamil	Delayed	Major	Established	DIGOXIN effects may be enhanced. Increased DIGOXIN levels and toxicity could occur.	Monitor DIGOXIN plasma concentrations and observe patients for signs of toxicity. Adjust the dose as needed. It may be necessary to decrease the DIGOXIN dosage.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	心臟用藥	OISM	ISOMIL S.C. TABLETS 40MG (VERAPAMIL) "Y.S."(鋁箔/	Verapamil	Delayed	Major	Established	DIGOXIN effects may be enhanced. Increased DIGOXIN levels and toxicity could occur.	Monitor DIGOXIN plasma concentrations and observe patients for signs of toxicity. Adjust the dose as needed. It may be necessary to decrease the DIGOXIN dosage.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES 120MG	Verapamil	Delayed	Major	Established	DIGOXIN effects may be enhanced. Increased DIGOXIN levels and toxicity could occur.	Monitor DIGOXIN plasma concentrations and observe patients for signs of toxicity. Adjust the dose as needed. It may be necessary to decrease the DIGOXIN dosage.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	降血壓藥	OCOV	CO-DIOVAN 80/12.5 FILN COATED TAB.	Hydrochlorothiazide	Delayed	Major	Probable	THIAZIDE-induced electrolyte disturbances may predispose to digitalis-induced arrhythmias.	Measure plasma levels of potassium and magnesium; supplement low levels. Prevent further losses with dietary sodium restriction or potassium-sparing diuretics.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	利尿劑	ODII	DITHIAZIDE TABLETS	Hydrochlorothiazide	Delayed	Major	Probable	THIAZIDE-induced electrolyte disturbances may predispose to digitalis-induced arrhythmias.	Measure plasma levels of potassium and magnesium; supplement low levels. Prevent further losses with dietary sodium restriction or potassium-sparing diuretics.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	降血壓藥	OHYZ	HYZAAR FC TABLETS 100/12.5 MG	Hydrochlorothiazide	Delayed	Major	Probable	THIAZIDE-induced electrolyte disturbances may predispose to digitalis-induced arrhythmias.	Measure plasma levels of potassium and magnesium; supplement low levels. Prevent further losses with dietary sodium restriction or potassium-sparing diuretics.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	Delayed	Major	Suspected	The pharmacologic effects of DIGOXIN may be increased. Elevated DIGOXIN levels with toxicity may occur.	Monitor patients for elevated DIGOXIN concentrations and signs of DIGOXIN toxicity when CYCLOSPORINE is given concomitantly. If evidence of DIGOXIN toxicity occurs, discontinue DIGOXIN and lower the dose when

一級交互作用

2011.07.05

心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	Delayed	Major	Suspected	The pharmacologic effects of DIGOXIN may be increased. Elevated DIGOXIN levels with toxicity may occur.	Monitor patients for elevated DIGOXIN concentrations and signs of DIGOXIN toxicity when CYCLOSPORINE is given concomitantly. If evidence of DIGOXIN toxicity occurs, discontinue DIGOXIN and lower the dose when
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	Delayed	Major	Suspected	The pharmacologic effects of DIGOXIN may be increased. Elevated DIGOXIN levels with toxicity may occur.	Monitor patients for elevated DIGOXIN concentrations and signs of DIGOXIN toxicity when CYCLOSPORINE is given concomitantly. If evidence of DIGOXIN toxicity occurs, discontinue DIGOXIN and lower the dose when
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	Delayed	Major	Suspected	The pharmacologic effects of DIGOXIN may be increased. Elevated DIGOXIN levels with toxicity may occur.	Monitor patients for elevated DIGOXIN concentrations and signs of DIGOXIN toxicity when CYCLOSPORINE is given concomitantly. If evidence of DIGOXIN toxicity occurs, discontinue DIGOXIN and lower the dose when
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Established	Coadministration of MACROLIDE AND RELATED ANTIBIOTICS and DIGOXIN may increase DIGOXIN serum levels; toxicity may occur. The effects of this interaction may persist for several weeks following ERYTHROMYCIN	Monitor for increased DIGOXIN levels and symptoms of toxicity; a decreased DIGOXIN dose may be necessary. The capsule formulation may increase bioavailability, thereby decreasing the likelihood of an interaction.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	利尿劑	ONAK	NAKAMIDE SR TABLETS 1.5MG "N.K"	Indapamide	Delayed	Major	Probable	THIAZIDE-induced electrolyte disturbances may predispose to digitalis-induced arrhythmias.	Measure plasma levels of potassium and magnesium; supplement low levels. Prevent further losses with dietary sodium restriction or potassium-sparing diuretics.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	降血壓藥複方	OPRT	PRETERAX SCORED TABLETS	Indapamide	Delayed	Major	Probable	THIAZIDE-induced electrolyte disturbances may predispose to digitalis-induced arrhythmias.	Measure plasma levels of potassium and magnesium; supplement low levels. Prevent further losses with dietary sodium restriction or potassium-sparing diuretics.

一級交互作用

2011.07.05

心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	心臟用藥	ORYT	RYTMONORM 150MG FILM COATED TABLETS	Propafenone	Delayed	Major	Established	Serum DIGOXIN levels may be increased, resulting in toxicity.	Monitor serum DIGOXIN levels and observe patients for toxicity. Adjust the DIGOXIN dose if PROPAPENONE is added to or discontinued from the treatment regimen.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	抗生素－巨環類	OZIS	ZITHROMAX POWDER FOR ORAL SUSPENSION	Azithromycin	Delayed	Major	Established	Coadministration of MACROLIDE AND RELATED ANTIBIOTICS and DIGOXIN may increase DIGOXIN serum levels; toxicity may occur. The effects of this interaction may persist for several weeks following ERYTHROMYCIN	Monitor for increased DIGOXIN levels and symptoms of toxicity; a decreased DIGOXIN dose may be necessary. The capsule formulation may increase bioavailability, thereby decreasing the likelihood of an interaction.
心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	抗生素－巨環類	OZIT	ZITHROMAX 250MG TABLETS	Azithromycin	Delayed	Major	Established	Coadministration of MACROLIDE AND RELATED ANTIBIOTICS and DIGOXIN may increase DIGOXIN serum levels; toxicity may occur. The effects of this interaction may persist for several weeks following ERYTHROMYCIN	Monitor for increased DIGOXIN levels and symptoms of toxicity; a decreased DIGOXIN dose may be necessary. The capsule formulation may increase bioavailability, thereby decreasing the likelihood of an interaction.
心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES 120MG	Verapamil	心臟用藥	OCAR	CARDIOLOL TABLETS 10MG (PROPRANOLOL)(鋁箔/膠箔)	Propranolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES	Verapamil	心臟用藥	OKEL	KERLONE 20MG, SCORED FILM-COATED TABLET	Betaxolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES 120MG	Verapamil	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Probable	Increased risk of cardiotoxicity.	Closely monitor cardiac function in patients receiving VERAPAMIL and certain MACROLIDE and RELATED ANTIBIOTICS.
心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES	Verapamil	心臟用藥	OTE1	TENORMIN TABLETS 100MG	Atenolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.
心臟用藥	OVEE	VERELAN SUSTAINED RELEASE CAPSULES	Verapamil	降血壓藥	OPIN	PINDOLOL TABLETS "TOWA"	Pindolol	Rapid	Major	Probable	Effects of both drugs may be increased.	Monitor cardiac function; reduce the doses as needed.

一級交互作用

2011.07.05

心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	Delayed	Major	Suspected	Severe myopathy or rhabdomyolysis may occur.	If coadministration of these agents cannot be avoided, use with caution and closely monitor creatine kinase
心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Probable	Severe myopathy or rhabdomyolysis may occur because of increased HMG-CoA REDUCTASE INHIBITOR levels.	If possible, administer alternative therapy. Fluvastatin (<trade-name>Lescol</trade-name>) and pravastatin (<trade-name>Pravachol</trade-name>) are not metabolized by CYP3A4, and may be less likely to interact. Advise patients to report unexplained muscle

一級交互作用

2011.07.05

心臟用藥複方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	抗生素－抗黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
未分類治療藥物	OCOL	COLCHICINE TABLETS 0.5MG "SHIONOGI"(鋁箔/膠	Colchicine	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	Increased COLCHICINE serum concentrations with toxicity (including death)may occur.	Avoid this combination. Use alternative treatment for gout or infection.
未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination

一級交互作用

2011.07.05

未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or

一級交互作用

2011.07.05

未分類治療藥物	OIMI	Imigran FDT Tablets 50mg	Sumatriptan	抗交感神經藥物複方	OSEL	SEGLOR CAP.	Dihydroergotamine	Rapid	Major	Suspected	The risk of vasospastic reactions may be increased.¹⁻⁶	Use of SELECTIVE 5-HT₁ RECEPTOR AGONISTS within 24 hours of treatment with an ergot-containing medication is contraindicated. Similarly, coadministration of two 5-HT₁ RECEPTOR AGONISTS within 24 hours of each
未分類治療藥物	OIMU	IMURAN AZATHIOPRINE TABLETS 50MG B.P.	Azathioprine	未分類治療藥物	OTON	TONSARIC TABLETS 100MG "S.T." (ALLOPURINOL)	Allopurinol	Delayed	Major	Established	Increases in pharmacologic and toxic effects of orally administered THIOPURINES have occurred with coadministration of ALLOPURINOL.	Reduced dosages of THIOPURINES are necessary when ALLOPURINOL is administered. It is suggested that the initial THIOPURINE doses be reduced to 25% or 33% of the recommended initial dose during coadministration and that hematologic function be closely moni
未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination

一級交互作用

2011.07.05

未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	The immunosuppressive effects of CYCLOSPORINE may be reduced. This appears to occur as early as 2 days following the initiation of RIFAMYCINS and may persist for 1 to 3 weeks after discontinuation.	Increased doses of CYCLOSPORINE may be necessary during concomitant RIFAMYCIN therapy. Frequent monitoring of CYCLOSPORINE concentrations and serum creatinine is required during RIFAMYCIN therapy and following its discontinuation. Avoid this combination
未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or

一級交互作用

2011.07.05

未分類治療藥物複方	OMD1	MADOPAR HBS CAPSULES 125MG "ROCHE"	Levodopa	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
未分類治療藥物複方	OMD2	MADOPAR TABLETS 250MG	Levodopa	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
未分類治療藥物複方	OS21	SINEMET 25/100 TABLETS(AUSTRALIA)	Levodopa	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
未分類治療藥物複方	OS22	SINEMET 25/250 TABLETS	Levodopa	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
利尿劑	ILAI	LASIX 20MG SOLUTION FOR INJECTION	Furosemide	心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	Delayed	Major	Probable	Diuretic-induced electrolyte disturbances may predispose to DIGITALIS-induced arrhythmias.	Measure plasma levels of potassium and magnesium when using these drugs in combination. Supplement patients with low levels. Prevent further losses with dietary sodium restriction or addition of potassium-sparing diuretics.
利尿劑	ILAI	LASIX 20MG SOLUTION FOR INJECTION	Furosemide	抗生素－胺基配糖體	ISRE	STREPTOMYCIN 1GM INJECTION "SINTONG"	Streptomycin	Rapid	Major	Suspected	Auditory toxicity may be increased. Hearing loss of varying degrees may occur. Irreversible hearing loss has occurred.	Perform baseline hearing testing and periodic monitoring. Avoid excessive doses. Reduced doses of 1 or both drugs may be necessary in patients with renal insufficiency.

一級交互作用

2011.07.05

利尿劑	ONAD	NADIS TABLETS(鋁箔/膠箔)	Furosemide	心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	Delayed	Major	Probable	Diuretic-induced electrolyte disturbances may predispose to DIGITALIS-induced arrhythmias.	Measure plasma levels of potassium and magnesium when using these drugs in combination. Supplement patients with low levels. Prevent further losses with dietary sodium restriction or addition of potassium-sparing diuretics.
利尿劑	ONAD	NADIS TABLETS(鋁箔/膠箔)	Furosemide	心臟用藥	OLAN	LANOXIN DIGOXIN TABLETS 0.25MG B.P.	Digoxin	Delayed	Major	Probable	Diuretic-induced electrolyte disturbances may predispose to DIGITALIS-induced arrhythmias.	Measure plasma levels of potassium and magnesium when using these drugs in combination. Supplement patients with low levels. Prevent further losses with dietary sodium restriction or addition of potassium-sparing diuretics.
利尿劑	ONAD	NADIS TABLETS(鋁箔/膠箔)	Furosemide	抗生素－胺基配糖體	ISRE	STREPTOMYCIN 1GM INJECTION "SINTONG"	Streptomycin	Rapid	Major	Suspected	Auditory toxicity may be increased. Hearing loss of varying degrees may occur. Irreversible hearing loss has occurred.	Perform baseline hearing testing and periodic monitoring. Avoid excessive doses. Reduced doses of 1 or both drugs may be necessary in patients with renal insufficiency.
妥因類	IALE	ALEVIATIN INJECTION	Phenytoin	擬交感神經興奮藥物	IDOP	DOPMIN 40MG/ML INFUSION	Dopamine	Rapid	Major	Suspected	The administration of PHENYTOIN during a DOPAMINE infusion may result in profound hypotension and possible cardiac arrest.	Use PHENYTOIN with extreme caution in patients receiving a DOPAMINE infusion. If PHENYTOIN must be administered, carefully monitor BP and discontinue the PHENYTOIN infusion if hypotension
妥因類	IALE	ALEVIATIN INJECTION	Phenytoin	抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	Delayed	Major	Suspected	HYDANTOIN plasma levels may be elevated, increasing the risk of toxicity, while VORICONAZOLE plasma levels may be reduced, decreasing the efficacy.	Monitor HYDANTOIN levels and adjust the dose as needed. In addition, it may be necessary to increase the dose of VORICONAZOLE during coadministration with a HYDANTOIN.
妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	擬交感神經興奮藥物	IDOP	DOPMIN 40MG/ML INFUSION	Dopamine	Rapid	Major	Suspected	The administration of PHENYTOIN during a DOPAMINE infusion may result in profound hypotension and possible cardiac arrest.	Use PHENYTOIN with extreme caution in patients receiving a DOPAMINE infusion. If PHENYTOIN must be administered, carefully monitor BP and discontinue the PHENYTOIN infusion if hypotension
妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	Delayed	Major	Suspected	HYDANTOIN plasma levels may be elevated, increasing the risk of toxicity, while VORICONAZOLE plasma levels may be reduced, decreasing the efficacy.	Monitor HYDANTOIN levels and adjust the dose as needed. In addition, it may be necessary to increase the dose of VORICONAZOLE during coadministration with a HYDANTOIN.

一級交互作用

2011.07.05

妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	Delayed	Major	Probable	CYCLOSPORINE concentrations are decreased by PHENYTOIN, resulting in a decrease in the immunosuppressive activity of CYCLOSPORINE, which may predispose patients to transplant rejection. This appears to occur within 48 hours of PHENYTOIN therapy and abate	Closely monitor CYCLOSPORINE concentrations during concurrent PHENYTOIN administration; tailor CYCLOSPORINE dosage to maintain concentrations in the therapeutic range.
妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	Delayed	Major	Probable	CYCLOSPORINE concentrations are decreased by PHENYTOIN, resulting in a decrease in the immunosuppressive activity of CYCLOSPORINE, which may predispose patients to transplant rejection. This appears to occur within 48 hours of PHENYTOIN therapy and abate	Closely monitor CYCLOSPORINE concentrations during concurrent PHENYTOIN administration; tailor CYCLOSPORINE dosage to maintain concentrations in the therapeutic range.
妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	CYCLOSPORINE concentrations are decreased by PHENYTOIN, resulting in a decrease in the immunosuppressive activity of CYCLOSPORINE, which may predispose patients to transplant rejection. This appears to occur within 48 hours of PHENYTOIN therapy and abate	Closely monitor CYCLOSPORINE concentrations during concurrent PHENYTOIN administration; tailor CYCLOSPORINE dosage to maintain concentrations in the therapeutic range.
妥因類	ODIL	DILANTIN KAPSEALS	Phenytoin	未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	CYCLOSPORINE concentrations are decreased by PHENYTOIN, resulting in a decrease in the immunosuppressive activity of CYCLOSPORINE, which may predispose patients to transplant rejection. This appears to occur within 48 hours of PHENYTOIN therapy and abate	Closely monitor CYCLOSPORINE concentrations during concurrent PHENYTOIN administration; tailor CYCLOSPORINE dosage to maintain concentrations in the therapeutic range.
抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	抗生素－青黴素類	IOXC	OXACILLIN SODIUM INJECTION "UNION"	Oxacillin	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.

一級交互作用

2011.07.05

抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	抗生素－青黴素類	IPEG3	PENICILLIN G SODIUM INJECTION "Y.F."	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	抗癌藥物複方	IPIC	PICIBANIL 5KE	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	抗生素－青黴素類	IRET	RETARPEN 2,400,000IU FOR INJECTION	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗生素－青黴素類	IOXC	OXACILLIN SODIUM INJECTION "UNION"	Oxacillin	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗生素－青黴素類	IPEG3	PENICILLIN G SODIUM INJECTION "Y.F."	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗癌藥物複方	IPIC	PICIBANIL 5KE	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗生素－青黴素類	IRET	RETARPEN 2,400,000IU FOR INJECTION	Penicillin G	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Suspected	The action of WARFARIN may be increased.	Monitor ANTICOAGULANT parameters frequently and adjust the WARFARIN dose accordingly if these agents must be coadministered. Instruct patients regarding the early signs and symptoms of bleeding.
抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	抗生素－青黴素類	ODIC	DICLOCIN CAPSULES (DICLOXACILLIN) "KINGDOM"	Dicloxacillin	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	心臟用藥	ILAN	LANOXIN DIGOXIN INJECTION 0.5MG B.P.	Digoxin	Delayed	Major	Established	Coadministration of MACROLIDE AND RELATED ANTIBIOTICS and DIGOXIN may increase DIGOXIN serum levels; toxicity may occur. The effects of this interaction may persist for several weeks following ERYTHROMYCIN	Monitor for increased DIGOXIN levels and symptoms of toxicity; a decreased DIGOXIN dose may be necessary. The capsule formulation may increase bioavailability, thereby decreasing the likelihood of an interaction.

一級交互作用

2011.07.05

抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	心臟用藥	IVER	VERPAMIL 2.5MG/ML INJECTION	Verapamil	Delayed	Major	Probable	Increased risk of cardiotoxicity.	Closely monitor cardiac function in patients receiving VERAPAMIL and certain MACROLIDE and RELATED ANTIBIOTICS.
抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	抗癌藥物	IVIL	VINBLASTINE SULFATE LYOPHILIZED INJECTION 10MG	Vinblastine	Delayed	Major	Suspected	The risk of VINBLASTINE toxicity (eg, constipation, myalgia, neutropenia) may be increased.	Avoid this drug combination. If VINBLASTINE and ERYTHROMYCIN must be given concurrently, administer a conservative dose of VINBLASTINE and closely monitor patients for VINBLASTINE
抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	抗交感神經藥物複方	OSEL	SEGLOR CAP.	Dihydroergotamine	Rapid	Major	Probable	Acute ergotism manifested as peripheral ischemia has been reported with concomitant use of these agents.	Monitor and counsel the patient to watch for signs of ergotism. The ERGOT preparation dosage may need to be decreased. One or both agents may require discontinuation. Sodium nitroprusside (eg, <trade-name>Nitropress</trade-name>) has been beneficial in re
抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	其他抗痙攣劑	OT-C	TEGRETOL CR 200MG FILM-COATED TABLETS (DIVISIBLE)	Carbamazepine	Rapid	Major	Established	CARBAMAZEPINE concentration/toxicity may be increased.	Avoid this combination if possible; otherwise, monitor CBZ levels, and closely observe the patient for toxicity. Consider stopping either drug, decreasing the CBZ dose or using an alternative macrolide (eg, azithromycin[<trade-name>Zithromax</trade-name>
抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	降血脂藥複方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	Severe myopathy or rhabdomyolysis may occur because of increased HMG-CoA REDUCTASE INHIBITOR levels.	If possible, administer alternative therapy. Fluvastatin (<trade-name>Lescol</trade-name>) and pravastatin (<trade-name>Pravachol</trade-name>) are not metabolized by CYP3A4, and may be less likely to interact. Advise patients to report unexplained muscle
抗生素－抗黴菌劑	IDIF	DIFLUCAN IV INJECTION	Fluconazole	抗癌藥物	IVII	VINCRISTINE SULFATE SOLUTION 1MG/ML	Vincristine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia) may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE

一級交互作用

2011.07.05

抗生素－抗 黴菌劑	IDIF	DIFLUCAN IV INJECTION	Fluconazole	抗癌藥物	IVIL	VINBLASTINE SULFATE LYOPHILIZED INJECTION 10MG	Vinblastine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia)may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	抗癌藥物	IVII	VINCRISTINE SULFATE SOLUTION 1MG/ML	Vincristine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia)may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	抗癌藥物	IVIL	VINBLASTINE SULFATE LYOPHILIZED INJECTION 10MG	Vinblastine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia)may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	心臟用藥複 方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	降血脂藥	OLI4	LIPITOR FILM- COATED TABLETS 40MG	Atorvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Established	The anticoagulant effect of WARFARIN may be increased.	Monitor PT and INR values frequently (eg, every 2 days) when adding or discontinuing an AZOLE ANTIFUNGAL AGENT. Adjust the WARFARIN dose as needed.

一級交互作用

2011.07.05

抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	降血脂藥	OLE8	LESCOL XL FILM- COATED TABLETS 80MG	Fluvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	OFUK	FLU-D CAPSULES 50MG	Fluconazole	降血脂藥複 方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	催產劑	IMTH	METHERGIN (R) AMPOULES 0.2MG/1ML	Methylergonovine	Delayed	Major	Suspected	The risk of ergot toxicity (eg, peripheral vasospasm, ischemia of the extremities) may be increased.	Coadministration of AZOLE ANTIFUNGAL AGENTS and ERGOT DERIVATIVES is contraindicated.
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	抗癌藥物	ITA2	TAXOTERE CONCENTRATE AND SOLVENT FOR SOLUTION FOR	Docetaxel	Delayed	Major	Suspected	TAXOID plasma concentrations may be elevated, increasing the pharmacologic effects and risk of toxicity (eg, neutropenia).	If coadministration of these agents cannot be avoided, give the TAXOID with caution and reduce the TAXOID dose as needed.
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	抗癌藥物	IVII	VINCRISTINE SULFATE SOLUTION 1MG/ML	Vincristine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia) may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	抗癌藥物	IVIL	VINBLASTINE SULFATE LYOPHILIZED INJECTION 10MG	Vinblastine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia) may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE

一級交互作用

2011.07.05

抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	心臟用藥複 方	OCAD	CADUET 5MG/10MG TABLET	Atorvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	降血脂藥	OLI4	LIPITOR FILM- COATED TABLETS 40MG	Atorvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Established	The anticoagulant effect of WARFARIN may be increased.	Monitor PT and INR values frequently (eg, every 2 days) when adding or discontinuing an AZOLE ANTIFUNGAL AGENT. Adjust the WARFARIN dose as needed.
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	降血脂藥	OLE8	LESCOL XL FILM- COATED TABLETS 80MG	Fluvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	抗交感神經 藥物複方	OSEL	SEGLOR CAP.	Dihydroergotamine	Delayed	Major	Suspected	The risk of ergot toxicity (eg, peripheral vasospasm, ischemia of the extremities) may be increased.	Coadministration of AZOLE ANTIFUNGAL AGENTS and ERGOT DERIVATIVES is contraindicated.

一級交互作用

2011.07.05

抗生素－抗 黴菌劑	ONIZ	KETOZOL TABLETS 200MG (KETOCONAZOLE)"W EIDAR"	Ketoconazole	降血脂藥複 方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－抗 黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	降血脂藥複 方	OVYT	VYTORIN TABLETS 10/20 MG	Simvastatin	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
抗生素－青 黴素類	IAN5	AMPICILLIN INJECTION 500 MG "CHI SHENG"	Ampicillin	抗生素－四 環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青 黴素類	IAUG	AUGMENTIN FOR INTRAVENOUS INJECTION 600MG, 1.2GM	Amoxicillin	抗生素－四 環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青 黴素類	OAU	AUGMENTIN TABLETS 375MG	Amoxicillin	抗生素－四 環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青 黴素類	OAU	AUGMENTIN TABLETS 375MG	Amoxicillin	抗生素－四 環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青 黴素類	OAUM	AUGMENTIN SYRUP 457MG/5ML /35ML	Amoxicillin	抗生素－四 環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青 黴素類	OAUM	AUGMENTIN SYRUP 457MG/5ML /35ML	Amoxicillin	抗生素－四 環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.

一級交互作用

2011.07.05

抗生素－青黴素類	OUNA	UNASYN TABLETS	Ampicillin	抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－青黴素類	OUNA	UNASYN TABLETS	Ampicillin	抗生素－四環素類	OBOR	BORYMYCIN CAPSULES 100MG (MINOCYCLINE)	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.
抗生素－胺基配糖體	IGM	GENTAMYCIN INJECTION	Gentamicin	利尿劑	ILAI	LASIX 20MG SOLUTION FOR INJECTION	Furosemide	Rapid	Major	Suspected	Auditory toxicity may be increased. Hearing loss of varying degrees may occur. Irreversible hearing loss has occurred.	Perform baseline hearing testing and periodic monitoring. Avoid excessive doses. Reduced doses of 1 or both drugs may be necessary in patients with renal insufficiency.
抗生素－胺基配糖體	IGM	GENTAMYCIN INJECTION	Gentamicin	骨骼肌鬆弛劑	IPAV	PAVULON 4MG=2ML	Pancuronium	Rapid	Major	Probable	The actions of the NONDEPOLARIZING MUSCLE RELAXANTS may be enhanced(eg, protracted respiratory depression).	Administer this combination only when necessary, then tailor dosage of the NONDEPOLARIZING MUSCLE RELAXANT, based on neuromuscular response. Provide ventilatory support as indicated.
抗生素－胺基配糖體	ONE2	NEOMYCIN CAP	Neomycin	骨骼肌鬆弛劑	IPAV	PAVULON 4MG=2ML	Pancuronium	Rapid	Major	Probable	The actions of the NONDEPOLARIZING MUSCLE RELAXANTS may be enhanced(eg, protracted respiratory depression).	Administer this combination only when necessary, then tailor dosage of the NONDEPOLARIZING MUSCLE RELAXANT, based on neuromuscular response. Provide ventilatory support as indicated.
抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	抗癌藥物	IVII	VINCRISTINE SULFATE SOLUTION 1MG/ML	Vincristine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia)may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	抗癌藥物	IVIL	VINBLASTINE SULFATE LYOPHILIZED INJECTION 10MG	Vinblastine	Delayed	Major	Probable	The risk of VINCA ALKALOID toxicity (eg, constipation, myalgia, neutropenia)may be increased.	Avoid coadministration of these agents whenever possible. If these agents must be coadministered, closely monitor the patient for VINCA ALKALOID toxicity. It may be necessary to discontinue the AZOLE
抗生素類複方	IUN1	UNASYN IM/IV FOR INJECTION 0.75G&1.5G	Ampicillin	抗生素－四環素類	IMIR	MIROSIN 100MG FOR INJECTION (MINOCYCLINE) "PANBIOT	Minocycline	Delayed	Major	Suspected	Pharmacologic and therapeutic action of PENICILLINS could be reduced.	Consider avoiding this combination if at all possible.

一級交互作用

2011.07.05

抗交感神經藥物複方	OSEL	SEGLOR CAP.	Dihydroergotamine	抗生素－抗黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	Delayed	Major	Suspected	The risk of ergot toxicity (eg, peripheral vasospasm, ischemia of the extremities) may be increased.	Coadministration of AZOLE ANTIFUNGAL AGENTS and ERGOT DERIVATIVES is contraindicated.
抗組織胺劑	OMI3	MINTAPP SYRUP "SINPHAR"	Phenylephrine	其他抗生素類	IZYV	ZYVOX INJECTION	Linezolid	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³ BRIMONIDINE is contraindicated in patients receiving
抗組織胺劑	OMI3	MINTAPP SYRUP "SINPHAR"	Phenylephrine	其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³ BRIMONIDINE is contraindicated in patients receiving
抗組織胺劑	OMI3	MINTAPP SYRUP "SINPHAR"	Phenylephrine	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³ BRIMONIDINE is contraindicated in patients receiving
抗結核劑	OISO	ISONIAZID TABLETS "WINSTON" (鋁箔/膠箔)	Isoniazid	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑	OISO	ISONIAZID TABLETS "WINSTON" (鋁箔/膠箔)	Isoniazid	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the

一級交互作用

2011.07.05

抗結核劑	OISO	ISONIAZID TABLETS "WINSTON" (鋁箔/膠箔)	Isoniazid	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑複方	ORIA	RIFATER S.C.TAB.	Isoniazid	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑複方	ORIA	RIFATER S.C.TAB.	Isoniazid	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑複方	ORIA	RIFATER S.C.TAB.	Isoniazid	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Isoniazid	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Isoniazid	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the

一級交互作用

2011.07.05

抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Isoniazid	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Probable	Hepatotoxicity may occur at a rate higher than with either agent alone.	If alterations in liver function tests occur, consider discontinuation of one or both of these agents. Although discontinuation of therapy is usually sufficient, close monitoring is necessary due to the severity of the
抗精神病藥	OCLO	CLOZARIL TABLETS 100MG	Clozapine	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Delayed	Major	Established	Serum CLOZAPINE levels may be elevated, resulting in increased pharmacologic and toxic effects.	Monitor CLOZAPINE serum levels and observe the clinical response. Adjust the dose of CLOZAPINE as
抗精神病藥	OCLO	CLOZARIL TABLETS 100MG	Clozapine	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Delayed	Major	Established	Serum CLOZAPINE levels may be elevated, resulting in increased pharmacologic and toxic effects.	Monitor CLOZAPINE serum levels and observe the clinical response. Adjust the dose of CLOZAPINE as
抗精神病藥	OCLO	CLOZARIL TABLETS 100MG	Clozapine	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Delayed	Major	Established	Serum CLOZAPINE levels may be elevated, resulting in increased pharmacologic and toxic effects.	Monitor CLOZAPINE serum levels and observe the clinical response. Adjust the dose of CLOZAPINE as
抗精神病藥	OHAI	HALIN TABLETS 5MG (HALOPERIDOL) "YU SHENG"	Haloperidol	抗躁症劑	OLID	LIDIN TABLETS 300MG (LITHIUM CARBONATE)	Lithium	Delayed	Major	Suspected	Alterations in consciousness, encephalopathy, extrapyramidal effects, fever, leukocytosis, and increased serum enzymes.	When this combination is used, monitor patients closely, particularly during the first 3 weeks of therapy. If an interaction is suspected, discontinue either drug. Institute supportive treatment for symptoms.
抗精神病藥	OR-S	RISPERDAL ORAL SOLUTION 1MG/ML	Risperidone	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Rapid	Major	Suspected	RISPERIDONE plasma concentrations may be elevated, increasing the risk of adverse reactions. Serotonin syndrome (eg, altered consciousness, CNS irritability, increased muscle tone, myoclonus) may occur.	Observe the clinical response to RISPERIDONE when starting, stopping, or changing the dose of FLUOXETINE or PAROXETINE, or when giving high doses of SERTRALINE (more than 100 mg/day). Adjust the RISPERIDONE
抗精神病藥	OR-S	RISPERDAL ORAL SOLUTION 1MG/ML	Risperidone	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Rapid	Major	Suspected	RISPERIDONE plasma concentrations may be elevated, increasing the risk of adverse reactions. Serotonin syndrome (eg, altered consciousness, CNS irritability, increased muscle tone, myoclonus) may occur.	Observe the clinical response to RISPERIDONE when starting, stopping, or changing the dose of FLUOXETINE or PAROXETINE, or when giving high doses of SERTRALINE (more than 100 mg/day). Adjust the RISPERIDONE

一級交互作用

2011.07.05

抗精神病藥	OR-S	RISPERDAL ORAL SOLUTION 1MG/ML	Risperidone	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Rapid	Major	Suspected	RISPERIDONE plasma concentrations may be elevated, increasing the risk of adverse reactions. Serotonin syndrome (eg, altered consciousness, CNS irritability, increased muscle tone, myoclonus) may occur.	Observe the clinical response to RISPERIDONE when starting, stopping, or changing the dose of FLUOXETINE or PAROXETINE, or when giving high doses of SERTRALINE (more than 100 mg/day). Adjust the RISPERIDONE
抗憂鬱劑	OCYM	CYMBALTA 30MG	Duloxetine	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Probable	Serotonin syndrome, including altered consciousness, CNS irritability, myoclonus, and shivering, may occur.	Do not coadminister. Allow at least 5 days after stopping DULOXETINE; 1 week after stopping NEFAZODONE or VENLAFAXINE; 2 weeks after stopping CITALOPRAM, ESCITALOPRAM, FLUVOXAMINE, PAROXETINE, or SERTRALINE; and 5 weeks after stopping FLUOXETINE
抗憂鬱劑	OMEY	MESYREL TABLETS 50MG (TRAZODONE HYDROCHLORIDE)" M.S	Trazodone	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Rapid	Major	Suspected	Plasma TRAZODONE levels may be elevated, resulting in increased pharmacologic and toxic effects with some SRIs. Serotonin syndrome (eg, irritability, increased muscle tone, shivering, myoclonus, altered consciousness) may occur.	If coadministration cannot be avoided, start with a low dose of the SRI or TRAZODONE and closely monitor the patient.
抗憂鬱劑	OMEY	MESYREL TABLETS 50MG (TRAZODONE HYDROCHLORIDE)" M.S	Trazodone	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Rapid	Major	Suspected	Plasma TRAZODONE levels may be elevated, resulting in increased pharmacologic and toxic effects with some SRIs. Serotonin syndrome (eg, irritability, increased muscle tone, shivering, myoclonus, altered consciousness) may occur.	If coadministration cannot be avoided, start with a low dose of the SRI or TRAZODONE and closely monitor the patient.
抗憂鬱劑	OMEY	MESYREL TABLETS 50MG (TRAZODONE HYDROCHLORIDE)" M.S	Trazodone	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Rapid	Major	Suspected	Plasma TRAZODONE levels may be elevated, resulting in increased pharmacologic and toxic effects with some SRIs. Serotonin syndrome (eg, irritability, increased muscle tone, shivering, myoclonus, altered consciousness) may occur.	If coadministration cannot be avoided, start with a low dose of the SRI or TRAZODONE and closely monitor the patient.

一級交互作用

2011.07.05

抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	擬交感神經 興奮藥物	OSEU	SEUDORIN TABLETS (PSEUDOEPHEDRINE HCL)(鋁箔/膠箔)	Pseudoephedrine	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³ BRIMONIDINE is contraindicated in patients receiving
抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Rapid	Major	Probable	Serotonin syndrome, including altered consciousness, CNS irritability, myoclonus, and shivering, may occur.	Do not coadminister. Allow at least 5 days after stopping DULOXETINE;1 week after stopping NEFAZODONE or VENLAFAXINE; 2 weeks after stopping CITALOPRAM, ESCITALOPRAM, FLUVOXAMINE, PAROXETINE, or SERTRALINE; and 5 weeks after stopping FLUOXETINE
抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	抗憂鬱劑	OTOA	TOFRANIL S.C. TABLETS 25MG (IMIPRAMINE HYDROCHLORI	Imipramine	Rapid	Major	Established	Hyperpyretic crises, convulsions, and death have occurred.	Do not administer TRICYCLIC ANTIDEPRESSANTS (TCAs) with or within 2 weeks of MAOI treatment.
抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	抗憂鬱劑	OWEB	WELLBUTRIN XL 150 MG TABLET "CANADA"	Bupropion	Delayed	Major	Suspected	Risk of acute BUPROPION toxicity may be increased.	Coadministration of BUPROPION and MAOIs is contraindicated. Allow at least 14 days to elapse between discontinuing an MAOI and starting
抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Rapid	Major	Probable	Serotonin syndrome, including altered consciousness, CNS irritability, myoclonus, and shivering, may occur.	Do not coadminister. Allow at least 5 days after stopping DULOXETINE;1 week after stopping NEFAZODONE or VENLAFAXINE; 2 weeks after stopping CITALOPRAM, ESCITALOPRAM, FLUVOXAMINE, PAROXETINE, or SERTRALINE; and 5 weeks after stopping FLUOXETINE
抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Rapid	Major	Probable	Serotonin syndrome, including altered consciousness, CNS irritability, myoclonus, and shivering, may occur.	Do not coadminister. Allow at least 5 days after stopping DULOXETINE;1 week after stopping NEFAZODONE or VENLAFAXINE; 2 weeks after stopping CITALOPRAM, ESCITALOPRAM, FLUVOXAMINE, PAROXETINE, or SERTRALINE; and 5 weeks after stopping FLUOXETINE

一級交互作用

2011.07.05

抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	Delayed	Major	Probable	The anticoagulant effect of WARFARIN may increase.	Monitor ANTICOAGULANT parameters when starting or discontinuing coadministration of an HMG-CoA REDUCTASE INHIBITOR. Atorvastatin (<trade-name>Lipitor</trade-name>)¹ and pravastatin (eg,<trade-name>Pravachol</trade-
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	H ₂ – 拮抗劑	ODEF	DEFENSE FILM COATED TABLETS (CIMETIDINE) "YUNG SHI	Cimetidine	Delayed	Major	Established	Increase in WARFARIN effects; possible hemorrhage.	Avoid this combination if possible; alternative H₂-ANTAGONISTS, such as nizatidine, appear unlikely to interact. If this combination is used, monitor anticoagulation parameters and tailor WARFARIN doses as needed.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	甲狀腺製劑	OELT	ELTROXIN TABLETS 100MCG "GERMANY"	Levothyroxine	Delayed	Major	Probable	The anticoagulant action of oral ANTICOAGULANTS is amplified during concurrent administration of THYROID HORMONES.	Closely observe for clinical signs of bleeding and monitor coagulation indices. Oral ANTICOAGULANT doses may need to be decreased during administration of THYROID HORMONES. Conversely, oral ANTICOAGULANT doses may need to be increased if concurrent THYRO
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	Delayed	Major	Established	FIBRIC ACIDS may increase the hypoprothrombinemic effects of oral ANTICOAGULANTS. Bleeding and death have occurred. Warfarin plasma levels are not affected.¹⁻⁵	If combined use cannot be avoided, monitor INR frequently when starting or stopping a FIBRIC ACID. Be prepared to adjust the ANTICOAGULANT dose. Advise patients to immediately report unusual
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗生素－巨環類	OKLS	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Probable	The anticoagulant effect of oral ANTICOAGULANTS may be increased. Hemorrhage has occurred.	Monitor anticoagulant parameters and adjust the dose frequently when starting or stopping MACROLIDE AND RELATED ANTIBIOTICS. Monitoring and adjusting ANTICOAGULANT dosage may be necessary for several days after stopping MACROLIDE AND

一級交互作用

2011.07.05

抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	降血脂藥	OLE8	LESCOL XL FILM-COATED TABLETS 80MG	Fluvastatin	Delayed	Major	Probable	The anticoagulant effect of WARFARIN may increase.	Monitor ANTICOAGULANT parameters when starting or discontinuing coadministration of an HMG-CoA REDUCTASE INHIBITOR. Atorvastatin (<trade-name>Lipitor</trade-name>)¹ and pravastatin (eg,<trade-name>Pravachol</trade-
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	非類固醇類 抗發炎劑	ON-T	NO-TON F.C. TABLETS 500MG "STANDARD"	Nabumetone	Delayed	Major	Probable	Increased ANTICOAGULANT activity and risk of bleeding.¹⁻⁹	Monitor patients closely and instruct them to report signs and symptoms of bleeding to their health care provider.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	巴比妥類	OPHE	PHENOBARBITAL TABLETS 30MG "U.L."	Phenobarbital	Delayed	Major	Established	BARBITURATES reduce the effects of ANTICOAGULANTS.	Patients receiving BARBITURATES will need modification of their ANTICOAGULANT dose. Monitor ANTICOAGULANT action and adjust doses as needed. Termination of BARBITURATE therapy will result in decreased ANTICOAGULANT requirements. Monitor patients for severe
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	非類固醇類 抗發炎劑	OPOS	PONSTAN KAPSEALS	Mefenamic Acid	Delayed	Major	Probable	Increased ANTICOAGULANT activity and risk of bleeding.¹⁻⁹	Monitor patients closely and instruct them to report signs and symptoms of bleeding to their health care provider.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗甲狀腺製劑	OPOU	POLUPI TABLET 50MG "PANBIOTIC" (鋁箔/膠箔)	Propylthiouracil	Delayed	Major	Suspected	The action of oral ANTICOAGULANTS may be changed during coadministration of THIOAMINES.	Monitor coagulation indices and observe for clinical signs of excessive or subtherapeutic responses to oral ANTICOAGULANTS during coadministration of THIOAMINES. Adjust the oral ANTICOAGULANT dosage as necessary.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	磺胺藥	OSAL	SALAZOPYRIN ENTABS	Sulfasalazine	Delayed	Major	Established	The anticoagulant effect of WARFARIN may be enhanced, resulting in hemorrhage.	Monitor the anticoagulant action of WARFARIN and adjust the dose as necessary.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗生素－抗 黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	Delayed	Major	Established	The anticoagulant effect of WARFARIN may be increased.	Monitor PT and INR values frequently (eg, every 2 days) when adding or discontinuing an AZOLE ANTIFUNGAL AGENT. Adjust the WARFARIN dose as needed.

一級交互作用

2011.07.05

抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	利尿酸劑	OSU1	SULFIN TAB. 100MG	Sulfinpyrazone	Delayed	Major	Established	The anticoagulant activity of WARFARIN will likely be enhanced; hemorrhage could occur.	Monitor coagulation parameters closely. Expect to decrease the WARFARIN dose when SULFINPYRAZONE treatment is initiated, and increase dosage when SULFINPYRAZONE is discontinued.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	非類固醇類 抗發炎劑	OSUO	SULINTON TABLETS 200MG (SULINDAC)"Y.S."	Sulindac	Delayed	Major	Probable	Increased ANTICOAGULANT activity and risk of bleeding.¹⁻⁹	Monitor patients closely and instruct them to report signs and symptoms of bleeding to their health care provider.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	降血脂藥複方	Ovyt	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Probable	The anticoagulant effect of WARFARIN may increase.	Monitor ANTICOAGULANT parameters when starting or discontinuing coadministration of an HMG-CoA REDUCTASE INHIBITOR. Atorvastatin (<trade-name>Lipitor</trade-name>)¹ and pravastatin (eg,<trade-name>Pravachol</trade-
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗癌藥物	Ox5	XELODA TABLETS 500MG	Capecitabine	Delayed	Major	Suspected	The anticoagulant effect of WARFARIN may be increased.	Carefully monitor coagulation parameters during and after chemotherapy. Adjust WARFARIN dosage as needed.
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗生素－巨環類	Ozis	ZITHROMAX POWDER FOR ORAL SUSPENSION	Azithromycin	Delayed	Major	Probable	The anticoagulant effect of oral ANTICOAGULANTS may be increased. Hemorrhage has occurred.	Monitor anticoagulant parameters and adjust the dose frequently when starting or stopping MACROLIDE AND RELATED ANTIBIOTICS. Monitoring and adjusting ANTICOAGULANT dosage may be necessary for several days after stopping MACROLIDE AND
抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	抗生素－巨環類	Ozit	ZITHROMAX 250MG TABLETS	Azithromycin	Delayed	Major	Probable	The anticoagulant effect of oral ANTICOAGULANTS may be increased. Hemorrhage has occurred.	Monitor anticoagulant parameters and adjust the dose frequently when starting or stopping MACROLIDE AND RELATED ANTIBIOTICS. Monitoring and adjusting ANTICOAGULANT dosage may be necessary for several days after stopping MACROLIDE AND

一級交互作用

2011.07.05

抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素－青黴素類	IAN5	AMPICILLIN INJECTION 500 MG "CHI SHENG"	Ampicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素類複方	IUN1	UNASYN IM/IV FOR INJECTION 0.75G&1.5G	Ampicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素－青黴素類	IAUG	AUGMENTIN FOR INTRAVENOUS INJECTION 600MG, 1.2GM	Amoxicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素－青黴素類	IOXC	OXACILLIN SODIUM INJECTION "UNION"	Oxacillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素－青黴素類	IPEG3	PENICILLIN G SODIUM INJECTION "Y.F."	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade

一級交互作用

2011.07.05

抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗癌藥物複方	IPIC	PICIBANIL 5KE	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg, <trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	抗生素－青黴素類	IRET	RETARPEN 2,400,000IU FOR INJECTION	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg, <trade
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	其他抗感染劑複方	ISEV	SEVATRIM INJECTION	Trimethoprim	Delayed	Major	Suspected	TRIMETHOPRIM may increase the risk of METHOTREXATE-induced bone marrow suppression and megaloblastic anemia.	If this drug combination cannot be avoided, closely monitor the patient for signs of hematologic toxicity. Leucovorin calcium (eg, <trade-name>Wellcovorin</trade-name>) may be necessary to treat megaloblastic anemia and neutropenia resulting from folic ac
抗癌藥物	IABI	ABITREXATE INJECTION, 25MG/ML	Methotrexate	其他抗感染劑複方	ISEV	SEVATRIM INJECTION	Sulfamethoxazole	Delayed	Major	Suspected	SULFONAMIDES may increase the risk of METHOTREXATE (MTX)-induced bone marrow suppression. MTX may predispose patients to TRIMETHOPRIM-SULFAMETHOXAZOLE(TMP-SMZ)-induced megaloblastic anemia.	If SULFONAMIDES cannot be avoided, closely monitor patients for signs of hematologic toxicity.
抗癌藥物	OEND	SYKLOFOSFAMID S.C. TABLETS 50MG	Cyclophosphamide	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Suspected	The anticoagulant effect of WARFARIN may be increased.	Carefully monitor coagulation parameters during and after chemotherapy. Adjust WARFARIN dosage as needed.
抗癌藥物	OET	VEPESID CAPSULES 50MG	Etoposide	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Suspected	The anticoagulant effect of WARFARIN may be increased.	Carefully monitor coagulation parameters during and after chemotherapy. Adjust WARFARIN dosage as needed.

一級交互作用

2011.07.05

抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	IAN5	AMPICILLIN INJECTION 500 MG "CHI SHENG"	Ampicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素類複方	IUN1	UNASYN IM/IV FOR INJECTION 0.75G&1.5G	Ampicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	OUNA	UNASYN TABLETS	Ampicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	IAUG	AUGMENTIN FOR INTRAVENOUS INJECTION 600MG, 1.2GM	Amoxicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	OAU	AUGMENTIN TABLETS 375MG	Amoxicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade

一級交互作用

2011.07.05

抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	OAUM	AUGMENTIN SYRUP 457MG/5ML /35ML	Amoxicillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	IOXC	OXACILLIN SODIUM INJECTION "UNION"	Oxacillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	IPEG3	PENICILLIN G SODIUM INJECTION "Y.F."	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗癌藥物複方	IPIC	PICIBANIL 5KE	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青黴素類	IRET	RETARPEN 2,400,000IU FOR INJECTION	Penicillin G	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade

一級交互作用

2011.07.05

抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	其他抗感染劑複方	ISEV	SEVATRIM INJECTION	Trimethoprim	Delayed	Major	Suspected	TRIMETHOPRIM may increase the risk of METHOTREXATE-induced bone marrow suppression and megaloblastic anemia.	If this drug combination cannot be avoided, closely monitor the patient for signs of hematologic toxicity. Leucovorin calcium (eg, <trade-name>Wellcovorin</trade-name>) may be necessary to treat megaloblastic anemia and neutropenia resulting from folic ac
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	其他抗感染劑複方	ISEV	SEVATRIM INJECTION	Sulfamethoxazole	Delayed	Major	Suspected	SULFONAMIDES may increase the risk of METHOTREXATE (MTX)-induced bone marrow suppression. MTX may predispose patients to TRIMETHOPRIM-SULFAMETHOXAZOLE(TMP-SMZ)-induced megaloblastic anemia.	If SULFONAMIDES cannot be avoided, closely monitor patients for signs of hematologic toxicity.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	Rapid	Major	Suspected	Increased toxic effects of METHOTREXATE may occur.	Decreased doses of METHOTREXATE or prolonged regimens of leucovorin rescue may be indicated when SALICYLATES are coadministered. Consider monitoring METHOTREXATE plasma levels to guide dosage adjustment.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	未分類治療藥物	OARH	ARHEUMA TABLETS 20MG "LOTUS"	Leflunomide	Delayed	Major	Suspected	Risk of serious adverse reactions, including hepatotoxicity and hematologic toxicity (eg, agranulocytosis, pancytopenia, thrombocytopenia), may be increased.	If coadministration of LEFLUNOMIDE and METHOTREXATE cannot be avoided, monitor ALT, AST, serum albumin, platelets, WBC, and hemoglobin or hematocrit monthly.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	非類固醇類抗發炎劑	OCAA	CATAFLAM 25MG SUGAR COATED TABLETS(鋁箔/膠箔)	Diclofenac	Delayed	Major	Suspected	Increased METHOTREXATE (MTX) toxicity, which is less likely to occur with weekly low-dose MTX regimens for rheumatoid arthritis (RA) and other inflammatory diseases.¹	Consider longer leucovorin rescue when giving NSAIDs and MTX at antineoplastic doses. Monitor for renal impairment that could predispose to MTX toxicity, for signs of MTX toxicity,^{2,3} and MTX levels if indicated.

一級交互作用

2011.07.05

抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	非類固醇類 抗發炎劑	OVO7	VOLTAREN RETARD 75MG SLOW RELEASE FILM- COATED TABL	Diclofenac	Delayed	Major	Suspected	Increased METHOTREXATE (MTX) toxicity, which is less likely to occur with weekly low-dose MTX regimens for rheumatoid arthritis (RA) and other inflammatory diseases.¹	Consider longer leucovorin rescue when giving NSAIDs and MTX at antineoplastic doses. Monitor for renal impairment that could predispose to MTX toxicity, for signs of MTX toxicity,^{2,3} and MTX levels if indicated.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	抗生素－青 黴素類	ODIC	DICLOCIN CAPSULES (DICLOXACILLIN) "KINGDOM"	Dicloxacillin	Delayed	Major	Probable	Serum METHOTREXATE (MTX) concentrations may be elevated, increasing the risk of toxicity.	Monitor patients for MTX toxicity and measure MTX concentrations twice a week for at least the first 2 weeks. The dose and duration of leucovorin rescue may need to be increased. If a broad-spectrum parenteral antibiotic is needed, ceftazidime (eg,<trade
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	非類固醇類 抗發炎劑	ON-T	NO-TON F.C. TABLETS 500MG "STANDARD"	Nabumetone	Delayed	Major	Suspected	Increased METHOTREXATE (MTX) toxicity, which is less likely to occur with weekly low-dose MTX regimens for rheumatoid arthritis (RA) and other inflammatory diseases.¹	Consider longer leucovorin rescue when giving NSAIDs and MTX at antineoplastic doses. Monitor for renal impairment that could predispose to MTX toxicity, for signs of MTX toxicity,^{2,3} and MTX levels if indicated.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	其他治療藥 物	ONET	NEOTIGASON CAPSULES 25MG	Acitretin	Delayed	Major	Suspected	The risk of hepatitis may be increased.	Coadministration of METHOTREXATE and ACITRETIN
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	非類固醇類 抗發炎劑	OPOS	PONSTAN KAPSEALS	Mefenamic Acid	Delayed	Major	Suspected	Increased METHOTREXATE (MTX) toxicity, which is less likely to occur with weekly low-dose MTX regimens for rheumatoid arthritis (RA) and other inflammatory diseases.¹	Consider longer leucovorin rescue when giving NSAIDs and MTX at antineoplastic doses. Monitor for renal impairment that could predispose to MTX toxicity, for signs of MTX toxicity,^{2,3} and MTX levels if indicated.
抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	磺胺藥	OSAL	SALAZOPYRIN EN- TABS	Sulfasalazine	Delayed	Major	Suspected	SULFONAMIDES may increase the risk of METHOTREXATE (MTX)-induced bone marrow suppression. MTX may predispose patients to TRIMETHOPRIM-SULFAMETHOXAZOLE(TMP-SMZ)-induced megaloblastic anemia.	If SULFONAMIDES cannot be avoided, closely monitor patients for signs of hematologic toxicity.

一級交互作用

2011.07.05

抗癌藥物	OMTX	TREXAN 2.5MG TABLETS	Methotrexate	非類固醇類 抗發炎劑	OSUO	SULINTON TABLETS 200MG (SULINDAC)"Y.S."	Sulindac	Delayed	Major	Suspected	Increased METHOTREXATE (MTX) toxicity, which is less likely to occur with weekly low-dose MTX regimens for rheumatoid arthritis (RA) and other inflammatory diseases.¹	Consider longer leucovorin rescue when giving NSAIDs and MTX at antineoplastic doses. Monitor for renal impairment that could predispose to MTX toxicity,^{2,3} and MTX levels if indicated.
其他止痛劑 及解熱劑	OMUA	MUACTION SUSTAINED RELEASE TABLETS 100MG "M.S." (T	Tramadol	抗憂鬱劑	OCYM	CYMBALTA 30MG	Duloxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
其他止痛劑 及解熱劑	OMUA	MUACTION SUSTAINED RELEASE TABLETS 100MG "M.S." (T	Tramadol	其他治療藥物	OLEA	LEXAPRO TABLETS 10MG	Escitalopram	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
其他止痛劑 及解熱劑	OMUA	MUACTION SUSTAINED RELEASE TABLETS 100MG "M.S." (T	Tramadol	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
其他止痛劑 及解熱劑	OMUA	MUACTION SUSTAINED RELEASE TABLETS 100MG "M.S." (T	Tramadol	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
其他止痛劑 及解熱劑	OMUA	MUACTION SUSTAINED RELEASE TABLETS 100MG "M.S." (T	Tramadol	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	抗憂鬱劑	OCYM	CYMBALTA 30MG	Duloxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Coadminister LINEZOLID and SRIs with caution. Because LINEZOLID has MAOI activity, allow at least 2 weeks between stopping LINEZOLID and starting an SRI.

一級交互作用

2011.07.05

其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	其他治療藥物	OLEA	LEXAPRO TABLETS 10MG	Escitalopram	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Coadminister LINEZOLID and SRIs with caution. Because LINEZOLID has MAOI activity, allow at least 2 weeks between stopping LINEZOLID and starting an SRI.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	未分類治療藥物複方	OMD1	MADOPAR HBS CAPSULES 125MG "ROCHE"	Levodopa	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	未分類治療藥物複方	OMD2	MADOPAR TABLETS 250MG	Levodopa	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	未分類治療藥物複方	OS21	SINEMET 25/100 TABLETS(AUSTRALIA)	Levodopa	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	未分類治療藥物複方	OS22	SINEMET 25/250 TABLETS	Levodopa	Rapid	Major	Established	Hypertensive reactions occur if LEVODOPA is administered to patients receiving MAOIs.	Do not coadminister. The monoamine oxidase (MAO)–type B inhibitor SELEGILINE is not associated with a hypertensive reaction and is used therapeutically in combination with LEVODOPA and dopa decarboxylase inhibitors.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	擬交感神經興奮藥物	OSEU	SEUDORIN TABLETS (PSEUDOEPHEDRINE HCL)(鋁箔/膠箔)	Pseudoephedrine	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³/sup> BRIMONIDINE is contraindicated in patients receiving

一級交互作用

2011.07.05

其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Coadminister LINEZOLID and SRIs with caution. Because LINEZOLID has MAOI activity, allow at least 2 weeks between stopping LINEZOLID and starting an SRI.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	抗憂鬱劑	OTOA	TOFRANIL S.C. TABLETS 25MG (IMIPRAMINE HYDROCHLORI	Imipramine	Rapid	Major	Established	Hyperpyretic crises, convulsions, and death have occurred.	Do not administer TRICYCLIC ANTIDEPRESSANTS (TCAs) with or within 2 weeks of MAOI treatment.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Coadminister LINEZOLID and SRIs with caution. Because LINEZOLID has MAOI activity, allow at least 2 weeks between stopping LINEZOLID and starting an SRI.
其他抗生素類	OZYV	ZYVOX TABLETS 600MG	Linezolid	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Coadminister LINEZOLID and SRIs with caution. Because LINEZOLID has MAOI activity, allow at least 2 weeks between stopping LINEZOLID and starting an SRI.
其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or

一級交互作用

2011.07.05

其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
其他治療藥物	OCRS	CRESTOR 10MG FILM-COATED TABLETS	Rosuvastatin	降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	Delayed	Major	Suspected	Severe myopathy or rhabdomyolysis may occur.	If coadministration of these agents cannot be avoided, use with caution and closely monitor creatine kinase
其他治療藥物	OLEA	LEXAPRO TABLETS 10MG	Escitalopram	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Probable	Serotonin syndrome, including altered consciousness, CNS irritability, myoclonus, and shivering, may occur.	Do not coadminister. Allow at least 5 days after stopping DULOXETINE; 1 week after stopping NEFAZODONE or VENLAFAXINE; 2 weeks after stopping CITALOPRAM, ESCITALOPRAM, FLUVOXAMINE, PAROXETINE, or SERTRALINE; and 5 weeks after stopping FLUOXETINE
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類抗發炎劑	OCAA	CATAFLAM 25MG SUGAR COATED TABLETS(鋁箔/膠箔)	Diclofenac	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類抗發炎劑	OVO7	VOLTAREN RETARD 75MG SLOW RELEASE FILM-COATED TABL	Diclofenac	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類抗發炎劑	OCE2	CELEBREX CAPSULE 200MG	Celecoxib	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.

一級交互作用

2011.07.05

其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	抗凝血劑	OCOUCOUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Established	ANTICOAGULANT activity may be enhanced. The adverse reactions of ASPIRIN on gastric mucosa and platelet function also may enhance the possibility of hemorrhage.	If concurrent use cannot be avoided, frequently monitor INR and adjust ANTICOAGULANT dose accordingly when starting or stopping SALICYLATE therapy. Instruct patients to report unusual bleeding or bruising if ASPIRIN or topical SALICYLATES and ANTICOAGULA
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類 抗發炎劑	ON-TNO-TON F.C. TABLETS 500MG "STANDARD"	Nabumetone	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	其他治療藥物	OPLVPLAVIX FILM- COATED TABLETS 75MG	Clopidogrel	Delayed	Major	Probable	Risk of life-threatening bleeding (eg, intracranial and GI hemorrhage)may be increased in high-risk patients with transient ischemic attack or ischemic stroke.	Avoid ASPIRIN use in high-risk patients with recent ischemic stroke or transient ischemic attack who are receiving CLOPIDOGREL.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	其他治療藥物	OTHBTHROMBIFREE F.C. TABLETS 75 MG	Clopidogrel	Delayed	Major	Probable	Risk of life-threatening bleeding (eg, intracranial and GI hemorrhage)may be increased in high-risk patients with transient ischemic attack or ischemic stroke.	Avoid ASPIRIN use in high-risk patients with recent ischemic stroke or transient ischemic attack who are receiving CLOPIDOGREL.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類 抗發炎劑	OPOS PONSTAN KAPSEALS	Mefenamic Acid	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.
其他治療藥物複方	OAGG	AGGRENOX MEDIFIED RELEASE CAPSULES	Aspirin	非類固醇類 抗發炎劑	OSUOSULINTON TABLETS 200MG (SULINDAC)"Y.S."	Sulindac	Delayed	Major	Suspected	Cardioprotective effect of low-dose uncoated ASPIRIN may be reduced. These agents also are gastric irritants.	Consider using analgesics that do not interfere with antiplatelet effect(eg, acetaminophen). In patients receiving IBUPROFEN and ASPIRIN, administer IBUPROFEN at least 8 hours before or 30 minutes after immediate-release ASPIRIN.

一級交互作用

2011.07.05

呼吸及大腦興奮劑	ORIT	RITALIN TABLETS 10MG (METHYLPHENIDATE)	Methylphenidate	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Delayed	Major	Suspected	Hypertensive crisis.	Monitor BP during combined MAOI and METHYLPHENIDATE use. DEXMETHYLPHENIDATE is contraindicated in patients receiving MAOI therapy, and also within a minimum of 14 days after discontinuation of an MAOI.
阿片類似藥	IFEN	FENTANYL INJ. 0.05MG/ML	Fentanyl	心臟用藥	ICOR	CORDARONE INJECTION	Amiodarone	Rapid	Major	Suspected	Profound bradycardia, sinus arrest, and hypotension have occurred.	Monitor hemodynamic function and administer inotropic, chronotropic, and pressor support as indicated. The bradycardia is usually unresponsive to atropine. Large doses of vasopressors (eg, epinephrine, phenylephrine) have been used.
阿片類似藥	IFEN	FENTANYL INJ. 0.05MG/ML	Fentanyl	抗生素－抗黴菌劑	IDIF	DIFLUCAN IV INJECTION	Fluconazole	Rapid	Major	Suspected	The pharmacologic effects and adverse reactions of certain OPIOID ANALGESICS may be increased.	Use caution when administering certain OPIOID ANALGESICS to patients receiving AZOLE ANTIFUNGAL AGENTS. Monitor for prolonged or recurrent respiratory depression. It may be necessary to administer a lower dose of the OPIOID ANALGESIC.
阿片類似藥	IFEN	FENTANYL INJ. 0.05MG/ML	Fentanyl	抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	Rapid	Major	Suspected	The pharmacologic effects and adverse reactions of certain OPIOID ANALGESICS may be increased.	Use caution when administering certain OPIOID ANALGESICS to patients receiving AZOLE ANTIFUNGAL AGENTS. Monitor for prolonged or recurrent respiratory depression. It may be necessary to administer a lower dose of the OPIOID ANALGESIC.
阿片類似藥	IPEH	PETHIDINE HYDROCHLORIDE INJECTION 50MG/ML	Meperidine	其他抗生素類	IZYV	ZYVOX INJECTION	Linezolid	Rapid	Major	Probable	Coadministration may result in agitation, diaphoresis, fever, and seizures, which may progress to coma, apnea, and death. These reactions may occur several weeks following withdrawal of the	Coadministration of these agents is contraindicated.
阿片類似藥	OTRO	TRAMADOL SANDOZ UNO 200MG RETARDTABLETTEN	Tramadol	抗憂鬱劑	OCYM	CYMBALTA 30MG	Duloxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.

一級交互作用

2011.07.05

阿片類似藥	OTRO	TRAMADOL SANDOZ UNO 200MG RETARDTABLETTEN	Tramadol	其他治療藥物	OLEA	LEXAPRO TABLETS 10MG	Escitalopram	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
阿片類似藥	OTRO	TRAMADOL SANDOZ UNO 200MG RETARDTABLETTEN	Tramadol	抗憂鬱劑	OSIZ	SINZAC CAP. 20MG	Fluoxetine	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
阿片類似藥	OTRO	TRAMADOL SANDOZ UNO 200MG RETARDTABLETTEN	Tramadol	抗憂鬱劑	OZOL	ZOLOFT FILM COATED TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
阿片類似藥	OTRO	TRAMADOL SANDOZ UNO 200MG RETARDTABLETTEN	Tramadol	抗憂鬱劑	OY-J	YOU-JET F.C. TABLETS 50MG	Sertraline	Delayed	Major	Suspected	Serotonin syndrome (eg, agitation, altered consciousness, ataxia, myoclonus, overactive reflexes, shivering) may occur.	Closely monitor patients for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.
非類固醇類 抗發炎劑	OCAA	CATAFLAM 25MG SUGAR COATED TABLETS(鋁箔/膠箔)	Diclofenac	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT activity and risk of bleeding.¹⁻⁹	Monitor patients closely and instruct them to report signs and symptoms of bleeding to their health care provider.
非類固醇類 抗發炎劑	OCE2	CELEBREX CAPSULE 200MG	Celecoxib	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT effects of WARFARIN.	If coadministration cannot be avoided, carefully monitor ANTICOAGULANT parameters when starting, stopping, or changing the dose of the NSAID.
非類固醇類 抗發炎劑	OVO7	VOLTAREN RETARD 75MG SLOW RELEASE FILM-	Diclofenac	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT activity and risk of bleeding.¹⁻⁹	Monitor patients closely and instruct them to report signs and symptoms of bleeding to their health care provider.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	心臟用藥	OAPO	APO-CAPTO 12.5MG TABLETS	Captopril	Delayed	Major	Probable	Combining ACE INHIBITORS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk (eg, renally impaired) patients.	Regularly monitor renal function and serum potassium levels in patients receiving these agents concurrently. Be prepared to adjust therapy as needed.

一級交互作用

2011.07.05

保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	心臟用藥	OBLP	BLOPRESS TAB. 8MG	Candesartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥	OCOV	CO-DIOVAN 80/12.5 FILN COATED TAB.	Valsartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥	ODI1	DIOVAN FILM-COATED TABLETS 160MG	Valsartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥複方	OEXF	EXFORGE FILM-COATED TABLET 5/80MG	Valsartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	鹼化劑	ODES	DESTONE TAB. 540MG "N.K" (POTASSIUM CITRATE)	Potassium Citrate	Delayed	Major	Established	POTASSIUM-SPARING DIURETICS will increase potassium retention and can produce severe hyperkalemia.	Do not use this combination without documented evidence that a patient has clinical symptoms of hypokalemia unresponsive to either agent alone. If the combination is required, the patient should have strict dietary counseling and close monitoring of seru

一級交互作用

2011.07.05

保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥	OHYZ	HYZAAR FC TABLETS 100/12.5 MG	Losartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	瀉劑及緩瀉劑複方	OM-G	MAGVAC ORAL SOLUTION	Potassium Bicarbonate	Delayed	Major	Established	POTASSIUM-SPARING DIURETICS will increase potassium retention and can produce severe hyperkalemia.	Do not use this combination without documented evidence that a patient has clinical symptoms of hypokalemia unresponsive to either agent alone. If the combination is required, the patient should have strict dietary counseling and close monitoring of seru
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥	OOLM	OLMETEC F.C TABLETS 20MG	Olmesartan	Delayed	Major	Suspected	Combining ANGIOTENSIN II RECEPTOR ANTAGONISTS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk patients (eg, renal impairment, type 2 diabetes).	Regularly monitor serum potassium concentrations and renal function in patients receiving these agents concurrently. Consider estimating Ccr in elderly patients and high-risk patients. Adjust therapy as needed.
保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spironolactone	降血壓藥複方	OPRT	PRETERAX SCORED TABLETS	Perindopril	Delayed	Major	Probable	Combining ACE INHIBITORS and POTASSIUM-SPARING DIURETICS may result in elevated serum potassium concentrations in certain high-risk (eg, renally impaired) patients.	Regularly monitor renal function and serum potassium levels in patients receiving these agents concurrently. Be prepared to adjust therapy as needed.
降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	降血脂藥	OLE8	LESCOL XL FILM-COATED TABLETS 80MG	Fluvastatin	Delayed	Major	Suspected	Severe myopathy or rhabdomyolysis may occur.	If coadministration of these agents cannot be avoided, use with caution and closely monitor creatine kinase
降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	降血脂藥複方	Ovyt	VYTORIN TABLETS 10/20 MG	Simvastatin	Delayed	Major	Suspected	Severe myopathy or rhabdomyolysis may occur.	If coadministration of these agents cannot be avoided, use with caution and closely monitor creatine kinase

一級交互作用

2011.07.05

降血脂藥	OLE8	LESCOL XL FILM-COATED TABLETS 80MG	Fluvastatin	抗生素—抗黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	未分類治療藥物	OEQU	EQUORAL SOFT CAPSULES 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	未分類治療藥物	OSN1	SANDIMMUN NEORAL SOFT GELATIN CAP. 100MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	未分類治療藥物	OSN2	SANDIMMUN NEORAL SOFT GELATIN CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	未分類治療藥物	OEQ2	EQUORAL SOFT CAPSULES 25MG	Cyclosporine	Delayed	Major	Probable	Increased levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	If coadministration cannot be avoided, consider reducing the dose of the HMG-CoA REDUCTASE INHIBITOR; carefully monitor the response. Advise patients to report any unexplained muscle pain, tenderness, or
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	降血脂藥	OFEN	FENOLIP-U TABLETS 160MG "C.H."	Fenofibrate	Delayed	Major	Suspected	Severe myopathy or rhabdomyolysis may occur.	If coadministration of these agents cannot be avoided, use with caution and closely monitor creatine kinase

一級交互作用

2011.07.05

降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Probable	Severe myopathy or rhabdomyolysis may occur because of increased HMG-CoA REDUCTASE INHIBITOR levels.	If possible, administer alternative therapy. Fluvastatin (<trade-name>Lescol</trade-name>) and pravastatin (<trade-name>Pravachol</trade-name>) are not metabolized by CYP3A4, and may be less likely to interact. Advise patients to report unexplained muscle
降血脂藥	OLI4	LIPITOR FILM-COATED TABLETS 40MG	Atorvastatin	抗生素－抗黴菌劑	OSPO	SPORANOX CAPSULE 100MG	Itraconazole	Rapid	Major	Probable	Increased plasma levels and adverse reactions (eg, rhabdomyolysis) of HMG-CoA REDUCTASE INHIBITORS may occur.	ITRACONAZOLE is contraindicated with HMG-CoA REDUCTASE INHIBITORS metabolized by CYP3A4.¹ If coadministration of other agents cannot be avoided, consider reducing the HMG-CoA REDUCTASE INHIBITOR dose and carefully monitor patient response. PRA
降血壓藥	OCAT	CATAPRES TABLETS 75UG (CLONIDINE HYDROCHLORIDE)	Clonidine	心臟用藥	OKEL	KERLONE 20MG, SCORED FILM-COATED TABLET	Betaxolol	Delayed	Major	Suspected	Potentially life-threatening increases in BP.	Closely monitor BP after initiation or discontinuation of CLONIDINE or a BETA-BLOCKER when they are given concurrently. Discontinue either agent gradually; preferably, discontinue the BETA-BLOCKER first.
降血壓藥	OCAT	CATAPRES TABLETS 75UG (CLONIDINE HYDROCHLORIDE)	Clonidine	心臟用藥	OTE1	TENORMIN TABLETS 100MG	Atenolol	Delayed	Major	Suspected	Potentially life-threatening increases in BP.	Closely monitor BP after initiation or discontinuation of CLONIDINE or a BETA-BLOCKER when they are given concurrently. Discontinue either agent gradually; preferably, discontinue the BETA-BLOCKER first.
降血壓藥	OCAT	CATAPRES TABLETS 75UG (CLONIDINE HYDROCHLORIDE)	Clonidine	抗憂鬱劑	OTOA	TOFRANIL S.C. TABLETS 25MG (IMIPRAMINE HYDROCHLORI	Imipramine	Rapid	Major	Probable	Loss of BP control and possible life-threatening elevations in BP.	Avoid combination of CLONIDINE and TRICYCLIC ANTIDEPRESSANTS if possible by using other antihypertensive agents or
降血壓藥	OCAT	CATAPRES TABLETS 75UG (CLONIDINE HYDROCHLORIDE)	Clonidine	降血壓藥	OPIN	PINDOLOL TABLETS "TOWA"	Pindolol	Delayed	Major	Suspected	Potentially life-threatening increases in BP.	Closely monitor BP after initiation or discontinuation of CLONIDINE or a BETA-BLOCKER when they are given concurrently. Discontinue either agent gradually; preferably, discontinue the BETA-BLOCKER first.

一級交互作用

2011.07.05

恩崑類藥	ICRA	CRAVIT IV SOLUTION FOR INFUSION 5MG/ML	Levofloxacin	抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN). ¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT effect of WARFARIN.	If possible, choose a non-quinolone antibiotic. Monitor ANTICOAGULANT activity more frequently when starting or stopping QUINOLONES and adjust the WARFARIN dose accordingly.
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	其他精神治療藥	OGEO	GEODON CAPSULES 40MG	Ziprasidone	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	ZIPRASIDONE is contraindicated in patients receiving GATIFLOXACIN, MOXIFLOXACIN, or SPARFLOXACIN and in patients receiving drugs that have demonstrated QT prolongation ¹ (eg, LEVOFLOXACIN ²).
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	抗生素－巨環類	OKL5	KLARICID FILM-COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN). ¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	止吐劑	ONOV	ROUMIN TABLETS "YU SHENG"	Prochlorperazine	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated. ¹ LEVOFLOXACIN should be avoided. ² and GATIFLOXACIN ³ and MOXIFLOXACIN ⁴ should be used with caution in patients receiving drugs that prolong the QTc interval(eg, PHENOTHIAZINES).<

一級交互作用

2011.07.05

恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	抗憂鬱劑	OTOA	TOFRANIL S.C. TABLETS 25MG (IMIPRAMINE HYDROCHLORI	Imipramine	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, TRICYCLIC ANTIDEPRESSANTS [TCAs]).¹ LEVOFLOXACIN should be avoided,² while GATIFLOXACIN³ and MOXIFLOXACIN⁴
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	抗生素－巨環類	OZIS	ZITHROMAX POWDER FOR ORAL SUSPENSION	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN).¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩崑類藥	OAVE	AVELOX FILM-COATED TAB. 400MG	Moxifloxacin	抗生素－巨環類	OZIT	ZITHROMAX 250MG TABLETS	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN).¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗生素－巨環類	IER	ERYTHROCIN LACTOBIONATE-I.V.	Erythromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN).¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.

一級交互作用

2011.07.05

恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗凝血劑	OCOUC	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT effect of WARFARIN.	If possible, choose a non–QUINOLONE antibiotic. Monitor ANTICOAGULANT activity more frequently when starting or stopping QUINOLONES and adjust the WARFARIN dose accordingly.
恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	其他精神治 療藥	OGEO	GEODON CAPSULES 40MG	Ziprasidone	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	ZIPRASIDONE is contraindicated in patients receiving GATIFLOXACIN, MOXIFLOXACIN, or SPARFLOXACIN and in patients receiving drugs that have demonstrated QT prolongation¹ (eg, LEVOFLOXACIN²).
恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗生素－巨 環類	OKL5	KLARICID FILM- COATED 500MG TABLETS	Clarithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN).¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	止吐劑	ONOV	ROUMIN TABLETS "YU SHENG"	Prochlorperazine	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated,¹ LEVOFLOXACIN should be avoided,² and GATIFLOXACIN³ and MOXIFLOXACIN⁴ should be used with caution in patients receiving drugs that prolong the QTc interval(eg, PHENOTHIAZINES).<
恩崑類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗憂鬱劑	OTOA	TOFRANIL S.C. TABLETS 25MG (IMIPRAMINE HYDROCHLORI	Imipramine	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, TRICYCLIC ANTIDEPRESSANTS [TCAs]).¹ LEVOFLOXACIN should be avoided,² while GATIFLOXACIN³ and MOXIFLOXACIN⁴

一級交互作用

2011.07.05

恩莧類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗生素－巨環類	OZIS	ZITHROMAX POWDER FOR ORAL SUSPENSION	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN). ¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩莧類藥	OCR5	CRAVIT F.C. TAB 500MG	Levofloxacin	抗生素－巨環類	OZIT	ZITHROMAX 250MG TABLETS	Azithromycin	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.	SPARFLOXACIN is contraindicated in patients receiving drugs that prolong the QTc interval (eg, ERYTHROMYCIN). ¹ Avoid LEVOFLOXACIN and use GATIFLOXACIN and MOXIFLOXACIN with caution in patients receiving MACROLIDE AND RELATED ANTIBIOTICS.
恩莧類藥	OSIF	SINFLO F.C.TAB. 200MG	Ofloxacin	心臟用藥	ICOR	CORDARONE INJECTION	Amiodarone	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased. ¹	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class I _A and class I _B ; ANTIARRHYTHMIC AGENTS.
恩莧類藥	OSIF	SINFLO F.C.TAB. 200MG	Ofloxacin	心臟用藥	OAMO	AMIORONE TAB. 200MG (AMIODARONE)	Amiodarone	Delayed	Major	Suspected	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased. ¹	Avoid GATIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, and OFLOXACIN in patients receiving class I _A and class I _B ; ANTIARRHYTHMIC AGENTS.
恩莧類藥	OSIF	SINFLO F.C.TAB. 200MG	Ofloxacin	抗凝血劑	OCOU	COUMADIN TABLETS 5MG	Warfarin	Delayed	Major	Probable	Increased ANTICOAGULANT effect of WARFARIN.	If possible, choose a non-quinolone antibiotic. Monitor ANTICOAGULANT activity more frequently when starting or stopping QUINOLONES and adjust the WARFARIN dose accordingly.

一級交互作用

2011.07.05

骨骼肌鬆弛劑	IPAV	PAVULON 4MG=2ML	Pancuronium	抗生素—胺基配糖體	ISRE	STREPTOMYCIN 1GM INJECTION "SINTONG"	Streptomycin	Rapid	Major	Probable	The actions of the NONDEPOLARIZING MUSCLE RELAXANTS may be enhanced(eg, protracted respiratory depression).	Administer this combination only when necessary, then tailor dosage of the NONDEPOLARIZING MUSCLE RELAXANT, based on neuromuscular response. Provide ventilatory support as indicated.
荷爾蒙劑與合成取代物質	OVEA	VENINA TABLETS	Medroxyprogesterone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
荷爾蒙劑與合成取代物質	OVEA	VENINA TABLETS	Medroxyprogesterone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
荷爾蒙劑與合成取代物質	OVEA	VENINA TABLETS	Medroxyprogesterone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
祛痰劑複方	OM-S	MEDICON SYRUP	Dextromethorphan	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Suspected	Hyperpyrexia, abnormal muscle movement, hypotension, coma, and death have been associated with coadministration of these agents.	Because of potential severity of reaction, avoid coadministration of these agents. Coadministration of DEXTROMETHORPHAN and RASAGILINE or SELEGILINE is contraindicated.^{1,2}
腎上腺素	OCO2	CORTISONE ACETATE TABLETS 25MG"PING LAWER"	Cortisone	擬副交感神經興奮藥物	OMES	MESTINON S.C. TABLETS 60MG (PYRIDOSTIGMINE BROMIDE	Pyridostigmine	Delayed	Major	Probable	CORTICOSTEROIDS antagonize the effects of ANTICHOLINESTERASES in myasthenia gravis. Profound muscular depression relatively refractory to ANTICHOLINESTERASES has occurred.	Occasional long-term benefits from CORTICOSTEROID therapy in myasthenia gravis occur. Consequently, combined use may be attempted under supervised conditions and with ready availability of life-support systems.
腎上腺素	OKEC	KENACORT TABLETS (TRIAMCINOLONE)" Y.Y."	Triamcinolone	擬副交感神經興奮藥物	OMES	MESTINON S.C. TABLETS 60MG (PYRIDOSTIGMINE BROMIDE	Pyridostigmine	Delayed	Major	Probable	CORTICOSTEROIDS antagonize the effects of ANTICHOLINESTERASES in myasthenia gravis. Profound muscular depression relatively refractory to ANTICHOLINESTERASES has occurred.	Occasional long-term benefits from CORTICOSTEROID therapy in myasthenia gravis occur. Consequently, combined use may be attempted under supervised conditions and with ready availability of life-support systems.

一級交互作用

2011.07.05

腎上腺素	OMET	METISONE TABLETS 4MG (METHYLPREDNISOLONE) "S.D."	Methylprednisolone	擬副交感神經興奮藥物	OMES	MESTINON S.C. TABLETS 60MG (PYRIDOSTIGMINE BROMIDE	Pyridostigmine	Delayed	Major	Probable	CORTICOSTEROIDS antagonize the effects of ANTICHOLINESTERASES in myasthenia gravis. Profound muscular depression relatively refractory to ANTICHOLINESTERASES has occurred.	Occasional long-term benefits from CORTICOSTEROID therapy in myasthenia gravis occur. Consequently, combined use may be attempted under supervised conditions and with ready availability of life-support systems.
黃體脂酮類	OME0	MEDRONE TABLETS 5MG "WEIDAR"	Medroxyprogesterone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OME0	MEDRONE TABLETS 5MG "WEIDAR"	Medroxyprogesterone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OME0	MEDRONE TABLETS 5MG "WEIDAR"	Medroxyprogesterone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OPN	PRIMOLUT-NOR TABLETS 5 MG	Norethindrone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OPN	PRIMOLUT-NOR TABLETS 5 MG	Norethindrone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OPN	PRIMOLUT-NOR TABLETS 5 MG	Norethindrone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OUTR	UTROGESTAN CAPSULES	Progesterone	抗結核劑	ORF3	RIFAMPIN CAPSULES 300MG	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
黃體脂酮類	OUTR	UTROGESTAN CAPSULES	Progesterone	抗結核劑複方	ORIA	RIFATER S.C.TAB.	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.

一級交互作用

2011.07.05

黃體脂酮類	OUTR	UTROGESTAN CAPSULES	Progesterone	抗結核劑複方	ORIF	RIFINAH 150 S.C. TABLETS	Rifampin	Delayed	Major	Suspected	RIFAMPIN may increase the elimination rate of PROGESTIN-containing oral contraceptive steroids.	Patients who require concurrent contraception and antitubercular therapy should avoid use of either oral contraceptives or RIFAMPIN.
催產劑	IMTH	METHERGIN (R) AMPOULES 0.2MG/1ML	Methylergonovine	抗生素類	IVFE	VFEND 200MG FOR SOLUTION FOR INJECTION	Voriconazole	Delayed	Major	Suspected	The risk of ergot toxicity (eg, peripheral vasospasm, ischemia of the extremities) may be increased.	Coadministration of AZOLE ANTIFUNGAL AGENTS and ERGOT DERIVATIVES is contraindicated.
補充溶液	OSLK	SLOW-K TABLETS 600MG	Potassium Chloride	保鉀利尿劑	OALC	ALDACTIN TABLETS(鋁箔/膠箔)	Spirolactone	Delayed	Major	Established	POTASSIUM-SPARING DIURETICS will increase potassium retention and can produce severe hyperkalemia.	Do not use this combination without documented evidence that a patient has clinical symptoms of hypokalemia unresponsive to either agent alone. If the combination is required, the patient should have strict dietary counseling and close monitoring of seru
擬交感神經興奮藥物	IDOP	DOPMIN 40MG/ML INFUSION	Dopamine	其他抗生素類	IZYV	ZYVOX INJECTION	Linezolid	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³/sup> BRIMONIDINE is contraindicated in patients receiving
擬交感神經興奮藥物	IEPH	EPHEDRINE HYDROCHLORIDE INJECTION	Ephedrine	其他抗生素類	IZYV	ZYVOX INJECTION	Linezolid	Rapid	Major	Established	Coadministration of an MAOI and an indirect- or mixed-acting SYMPATHOMIMETIC may cause hypertensive crisis.¹⁻¹⁴ Direct-acting agents may interact minimally.¹⁵	Avoid coadministration. If used together and hypertension develops, administer phentolamine. RASAGILINE is contraindicated in patients receiving SYMPATHOMIMETICS.¹³/sup> BRIMONIDINE is contraindicated in patients receiving
擬交感神經興奮藥物	OATO	ATOCK TABLETS 40UG	Formoterol	心臟用藥	OCAR	CARDIOLOL TABLETS 10MG (PROPRANOLOL)(鋁箔/膠箔)	Propranolol	Rapid	Major	Suspected	Pharmacologic effects of SYMPATHOMIMETIC BETA-AGONISTS may be antagonized by BETA-BLOCKERS. Bronchospasm may occur.	If possible, avoid coadministration of these agents. If a BETA-BLOCKER is necessary, consider cautiously using a cardioselective BETA-BLOCKER.
擬交感神經興奮藥物	OATO	ATOCK TABLETS 40UG	Formoterol	降血壓藥	OPIN	PINDOLOL TABLETS "TOWA"	Pindolol	Rapid	Major	Suspected	Pharmacologic effects of SYMPATHOMIMETIC BETA-AGONISTS may be antagonized by BETA-BLOCKERS. Bronchospasm may occur.	If possible, avoid coadministration of these agents. If a BETA-BLOCKER is necessary, consider cautiously using a cardioselective BETA-BLOCKER.

鎮咳劑複方	OM-A	MEDICON-A CAPSULES	Dextromethorphan	抗憂鬱劑	OSEG	SEGININE TABLETS 5MG (SELEGILINE) "S.S.P."	Selegiline	Rapid	Major	Suspected	Hyperpyrexia, abnormal muscle movement, hypotension, coma, and death have been associated with coadministration of these agents.	Because of potential severity of reaction, avoid coadministration of these agents. Coadministration of DEXTROMETHORPHAN and RASAGILINE or SELEGILINE is contraindicated. ^{1,2}
-------	------	-----------------------	------------------	------	------	--	------------	-------	-------	-----------	--	---